Engflag

Avil INJ

Quick links to important sections

Avil INJ

Avil INJ_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avil INJ

Quick Facts

Property Description
Active ingredient Pheniramine Maleate
Form Solution for Injection (INJ)
Pharmacological Class First-Generation Antihistamine (Hsubscript1-receptor antagonist)
General Purpose Symptomatic relief of acute allergic reactions
Origin Synthetic Compound (Propylamine derivative)

What is Avil INJ and its Core Composition?

Avil INJ is a prescription-only medicinal preparation designated for systemic use, containing the single active ingredient Pheniramine Maleate. This compound is a synthetic organic chemical derived from Propylamine, a characteristic defining its core chemical structure and pharmacological properties. The product is formulated as a sterile Solution for injection within an ampoule, consisting of the Pheniramine Maleate dissolved in an appropriate aqueous vehicle.

Classifying Avil INJ: A First-Generation Hsubscript1-Receptor Antagonist

Avil INJ belongs to the Pharmacological class of Antihistamines, specifically categorized as a first-generation Hsubscript1-receptor antagonist. This means the medicine is designed to block the effects of histamine, a key chemical mediator released during allergic responses. The Pheniramine Maleate compound is clinically recognized for its Hsubscript1 blocking action, which helps to counteract the physiological changes associated with allergic episodes, thereby providing rapid symptomatic relief from the manifestations of acute allergic reactions.

Why is Avil INJ Administered Parenterally?

The INJ designation in the name Avil INJ explicitly signifies that the medication's intended route of administration is Parenteral (via injection). This specialized format, the Solution for injection, is a differentiating factor from the more common oral forms. It facilitates a rapid onset of a systemic effect, which is medically essential for effective intervention during acute hypersensitivity reactions where an immediate therapeutic response is necessary to manage systemic symptoms.

What side effects are possible with Avil INJ?

Possible side effects and safety information

The safety profile for Avil INJ (Pheniramine Maleate Injection) is structured around categories of adverse reactions as documented in official regulatory labeling. This medicine is classified as a first-generation antihistamine, and its most frequent effects relate to Central Nervous System (CNS) depression.

Regulatory Classification of Adverse Effects

Adverse reactions are formally classified by frequency and by System-Organ Class (SOC) in official prescribing information.

Classification Examples of Officially Listed Effects
Very Common / Common Sedation, Somnolence (drowsiness), Disturbance in attention, Dizziness, Dry mouth, Lassitude.
Rare / Very Rare Severe blood dyscrasias (e.g., Agranulocytosis, Aplastic Anemia), Convulsions, Toxic Psychosis.

CNS disorders, Gastrointestinal disorders, and Blood and Lymphatic System disorders are among the principal organ classes affected according to official documentation.

Safety Considerations for Specific Populations

Regulatory documents highlight that children and older adults may be more susceptible to CNS effects, including the potential for paradoxical excitation (restlessness or nervousness) rather than the expected sedation. Furthermore, caution is officially advised for use in patients with severe hepatic or severe renal impairment.

Safety-Related Restrictions

The label defines restrictions for use in certain situations. The medicine is not to be used in newborn or premature infants. Use is constrained in patients with pre-existing conditions that may be aggravated by the medicine's anticholinergic action, such as symptomatic prostatic hypertrophy (risk of urinary retention) or narrow-angle glaucoma. Sedation, a common effect, is officially noted to often diminish after a few days of exposure as tolerance develops.

Overdose and Emergency Response

Overdose Manifestations and Documented Risks

Pheniramine Maleate Injection overdose is officially documented to present as a complex toxicological state primarily affecting the central nervous system (CNS) and peripheral cholinergic function. Overdose symptoms may include profound drowsiness, extreme confusion, or, conversely, CNS excitation, agitation, and hallucinations. Anticholinergic signs, such as dry mouth, dilated pupils (mydriasis), and urinary retention, are also documented presentations. Life-threatening manifestations officially recognized in the regulatory profile include generalized convulsions, severe cardiac arrhythmias (such as QRS widening), and respiratory failure, leading to the potential for cardiorespiratory arrest and death.

Required Emergency Action

The official regulatory guidance mandates that immediate medical help be sought right away, or emergency services contacted, if an overdose is suspected. Urgent medical attention is specifically required upon the observation of severe signs, including seizures, difficulty breathing, an irregular heartbeat, or inability to be awakened. Since no specific antidote is known for Pheniramine Maleate overdose, management involves immediate symptomatic and supportive treatment under hospital monitoring, often requiring constant cardiac observation. Special considerations are noted for children, who may exhibit increased paradoxical excitation, and the elderly, who are at higher risk for confusion.

Therapeutic Uses of Avil INJ

What Avil INJ Treats: Main Uses and Benefits

This injectable formulation is applied across domains where additional symptomatic support is needed, addressing symptoms that create noticeable physiological strain and interfere with daily functioning. Avil INJ is commonly used across conditions presenting with acute episodes of hypersensitivity.

Acute Symptom Management and Supportive Relief

Avil INJ is considered relevant for easing symptoms related to various allergic reactions. It is applied in addressing symptoms that may become intense or disruptive such as widespread hives (urticaria), generalized severe itching, and symptoms associated with rapid onset of swelling (angioedema).

It is applied in clinical settings that involve acute or unstable symptom patterns, and is applied during phases of increased distress or discomfort. The use of Avil INJ contributes to easing the overall symptom load, and is relevant for easing discomfort when symptoms interfere with daily comfort. Furthermore, the medication may assist in addressing the associated secondary symptoms of nausea and vomiting that often accompany episodes of vertigo or motion sickness.

Quick Fact Relief for
Primary Focus Conditions presenting with acute allergic episodes
Symptom Cluster Symptoms related to inflammatory or irritative states and systemic imbalance
Therapeutic Role Supportive symptom management

Eligibility and Restrictions for Use

Who Can and Cannot Use Avil INJ?

The population eligibility for Avil INJ (Pheniramine Maleate Injection) is strictly defined by regulatory authorities based on age, physiological status, and underlying patient conditions.

Populations for Whom Use is Contraindicated

Absolute exclusion from using Avil INJ is specified for several patient groups, including newborn and premature infants and children under one year old. Use is also contraindicated in patients with a known hypersensitivity to the drug or any of its ingredients, and in individuals who have received Monoamine Oxidase (MAO) Inhibitors within the previous fourteen days. Some regulatory documents also list use as contraindicated in patients with lower respiratory tract diseases, including asthma, and those in pre-coma states.

Restricted and Conditional Use

Population / Condition Regulatory Status
Pregnancy and Lactation Contraindicated or Should Be Avoided (due to insufficient data)
Elderly Patients Use requires caution and close monitoring.
Comorbidities Use requires caution in patients with narrow-angle glaucoma, prostatic hypertrophy, severe cardiovascular disease, or epilepsy.

The standard labeled population is adult patients and pediatric patients over one year of age, though caution is advised for children due to increased susceptibility to effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for the active ingredient, Pheniramine Maleate, as detailed in government regulatory labeling. The interactions are classified based on the potential for additive effects or specific restrictions.

Formal Restrictions and Contraindications

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, meaning this combination must be avoided. Regulatory text requires that the medicine is not administered during, or within 14 days of discontinuing, MAOI therapy. This restriction is mandated because MAOIs prolong and intensify the anticholinergic effects of the antihistamine.

Pharmacodynamic Interaction Risks

Interactions documented in official prescribing information primarily involve the risk of additive effects. Concurrent use with other Central Nervous System (CNS) Depressants, such as opioid pain relievers, hypnotics, antipsychotics, and muscle relaxants, may cause additive CNS depression leading to profound sedation. Similarly, co-administration with other Anticholinergic Agents may lead to a potentiation and additive increase in anticholinergic effects.

Interactions with Substances

Official warnings also address substances such as Alcohol and Cannabis (Marijuana). Co-use with these substances may increase drowsiness and dizziness, contributing to the overall risk of CNS depression. No specific pharmacokinetic (enzyme or transporter-mediated) interactions are uniformly documented in the single-agent regulatory labels.

Mechanism of Action

How Avil INJ Works

Primary Action: Blocking Histamine H1 Receptors

This drug acts as an antagonist on the Histamine H1 receptors, preventing the natural chemical histamine from binding and activating these receptors. This mechanistic blockade initiates signaling sequences that influence the downstream effects of histamine release, resulting in altered capillary permeability and decreased tissue fluid movement.

Central Nervous System (CNS) Pathway Modulation

To some extent, the drug crosses the blood-brain barrier and influences H1 receptors and other signaling pathways within the CNS. This activity modulates the signaling within the brain's alertness centers, which results in a physiological consequence characterized by reduced vigilance.

Secondary Action: Anticholinergic Mechanism

A secondary part of the drug's mechanism involves a minor affinity for muscarinic acetylcholine receptors in peripheral tissues. This interaction modifies early molecular steps in the cholinergic system, resulting in the physiological consequence of reduced glandular secretions.

Dosage and Administration Information

How Avil INJ Is Used

This section describes the administration principles and dosing patterns for Avil INJ (Pheniramine Maleate Injection). The medicine is designated strictly for parenteral administration in a supervised clinical setting.

Administration Scope and Dosing

Instruction Detail
Route of Administration Intramuscular (IM) injection and Slow Intravenous (IV) injection are the approved routes of delivery.
Standard Adult Dose (aged 12+) The typical single dose ranges from 22.75 mg to 45.5 mg (1 ml to 2 ml). The maximum daily dose is regulated and should not exceed 3 mg per kilogram of body weight.
Frequency Pattern The dose is administered for short-term, acute management and is given typically once or twice a day. Repetition may occur at 12-hourly intervals until the acute requirement is resolved.
Preparation and Conditions Intravenous administration is subject to a strict rate constraint; it must be performed slowly, generally not exceeding 1 ml per minute. Dilution may be necessary to facilitate this slow IV delivery.

Population-Specific Administration Rules

Established protocols are followed based on the patient population:

  • Pediatric Use: For infants and children up to 12 years of age, the administration of the injection is restricted to the Intramuscular (IM) route only. Dosing in this group is managed according to the weight-based maximum daily limit.
  • Hepatic Impairment: Dosing requires careful consideration, and a reduction in the administered dose may be necessary for patients who present with severe hepatic impairment.

These instructions establish a standardized protocol focused on dose control, supervised parenteral delivery, and age-specific route requirements, ensuring the medicine is used as a short-term, episodic intervention only while the administration criteria are met.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Avil INJ

Evidence for Use in Acute Allergic Reactions

Research for Pheniramine Maleate injection was studied for understanding its role in the immediate management of symptoms related to acute allergic events. Studies, including Pharmacokinetic (PK) analyses, have been conducted to evaluate how quickly the medicine is absorbed and distributed throughout the body following an intravenous injection. This type of research is relevant in trials assessing short-term or episodic symptom patterns and the design of the injectable formulation.

The findings from these short-term comparative studies describe patterns observed during the initial hours of treatment for patients experiencing acute allergic signs like itching and swelling. The research reports indicate that the injection achieves high concentrations in the bloodstream quickly, which is consistent with the formulation's design for acute, temporary interventions during phases of heightened symptom activity.

Research on Urticaria (Hives) and Angioedema Symptoms

Clinical research has evaluated the injection for managing the acute, noticeable signs of urticaria (hives) and angioedema (swelling). Studies have been primarily short-term, sometimes using Randomized Controlled Trials (RCTs) to explore the use of Pheniramine or closely related compounds. This research examined outcomes related to physical discomfort and changes linked to inflammatory or irritative states in the skin.

Researchers monitored how symptoms evolved in the observed populations, focusing on metrics like the severity of itching reported by the patient and objective measurements of the size and number of wheals. The evidence quality varies across studies, as trials may be influenced by small sample sizes or the simultaneous use of other medications.

What is Still Uncertain About the Research Base

While research describes the physical and chemical characteristics of the injection, the evidence base largely relies on older studies. Limited large-scale, modern clinical trials specifically compare IV Pheniramine against a variety of current treatments. Consequently, long-term effects are not fully established, and comparative evidence is lacking against many newer medical options. The research landscape highlights what PK studies described regarding the high concentrations in the bloodstream and what is still uncertain—its long-term profile and specific findings across diverse patient groups.

Frequently Asked Questions (FAQ)

Common questions about Avil INJ (FAQ)

Q: What are the safety concerns for children receiving the injection?

Official regulatory safety information indicates that caution is necessary when this medicine is administered to children. Children may be more sensitive to the effects on the central nervous system (CNS) and have an increased risk of paradoxical excitation, which means they might become restless or nervous instead of experiencing the expected drowsiness. Official guidance indicates that for children under 12 years of age, administration is restricted to the intramuscular (IM) route only.

Q: How quickly does the injection start working (onset of action)?

The injection is formulated to provide a rapid systemic effect, consistent with its intended use for acute allergic reactions. According to official studies, the specialized format allows the medication to quickly achieve high concentrations in the bloodstream after administration. While a precise time in minutes is not uniformly provided, this fast action is a key characteristic noted in the product's official information.

Q: What is the difference between Avil INJ and the tablet form?

Official product information suggests the main difference is the route of administration and the intended setting for use. The INJ designation means the medicine is formulated as a Solution for Injection, designed for parenteral use (via injection) to facilitate a rapid, systemic effect. This specialized format is used for acute interventions, distinguishing it from an oral (tablet) form.

Q: Does Avil INJ expire, and is it still safe to use past the printed date?

Avil INJ has a defined shelf life, indicated by the expiry date printed on the carton. Regulatory instructions specifically state that the medicine must not be used after this expiry date. This date represents the period during which the medicine is expected to remain chemically stable and safe for use, provided it is stored correctly.

Q: What is the procedure for healthcare waste disposal of Avil INJ?

Official instructions indicate that any unused portion of the medicine should be disposed of properly by your healthcare professional (doctor or nurse). The medicine should not be discarded via household waste or poured down the sink, which adheres to standard regulatory protocols for medical waste.

How should Avil INJ be stored and disposed of?

How to Store and Dispose of Avil INJ

Avil Injection (Pheniramine Maleate) must be stored and handled according to the instructions provided to your healthcare professional.

Storage Requirement Official Guidance
Unopened Storage Does not require any special storage conditions.
Child Protection Keep out of the sight and reach of children.
Expiry Date Do not use after the expiry date printed on the carton.
Post-Opening Stability The medicine should be used immediately after opening. Any unused portion must be discarded.
Disposal Medicines should not be thrown away via wastewater or household waste. Your doctor or nurse is responsible for the proper disposal of any unused or no longer required medicine.

Note: Immediate use is required after opening to maintain microbiological safety, even if chemical stability is noted for a longer period in specific dilutions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Avil INJ found in:

A-Z Index: